Summary
The incidence of infections caused by gramnegative bacteria is increased in patients with multiple myeloma due to secondary humoral immunodeficiency. In order to diagnose patients with increased susceptibility to gram-negative infections, serum antibodies against common determinants of lipopolysaccharides (lipid A and core-polysaccharide) were determined by a rapid enzyme-linked immunosorbent assay (ELISA). It was possible to define a group of patients at high risk of contracting gram-negative infections using this test. Intravenous IgG preparations used as a substitute were shown to contain antibodies against these common antigens. However, it is suggested that the clinically recognized efficacy of these preparations could be due to their containing anti-LPS antibodies.
Zusammenfassung
Aufgrund ihres sekundären humoralen Immundefektes treten bei Patienten mit multiplem Myelom gehäuft Infektionen durch gramnegative Bakterien auf. Um Patienten mit einer erhöhten Anfälligkeit für gramnegative Infektionen zu diagnostizieren, wurden die Serum-Antikörper gegen gemeinsame Determinanten der Lipopolysaccharide (Lipid A und zentrales Polysaccharid) in einem schnellen enzymverbundenen Immunbindungstest (ELISA) bestimmt. Mit diesem Test-system war es möglich, eine Gruppe von Patienten mit einem hohen Risiko für gramnegative Infektionen zu definieren. Es wurde gezeigt, daß IgG-Präparationen, die zur intravenösen Substitution verwendet werden, Antikörper gegen diese gemeinsamen Antigene enthalten. Dabei ist zu vermuten, daß die klinisch gefundene Wirksamkeit dieser Präparationen auf ihrem Gehalt an anti-LPS-Antikörpern beruhen könnte.
Similar content being viewed by others
Literature
Barandun, S., Morell, A., Skvaril, F., Keller, H. Immunopertubation in paraproteinemia. Birth Defects (Original Article Series) 11 (1975) 95–98.
Cohen, H. J., Rundles, R. W. Managing the complications of plasma cell myeloma. Arch. Intern. Med. 135 (1975) 177–184.
Schedel, I. Intravenöse Immunglobulinsubstitution bei Patienten mit multiplem Myelom, Morbus Waldenström und chronischer lymphatischer Leukämie. In:Schmidt, R. E., Stroehmann, I. (eds.): Immunglobulintherapie — Grundlagen und klinische Anwendung. Karger, Basel 1983, pp. 52–58.
Twomey, J. J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch. Intern. Med. 132 (1973) 562–565.
Meyers, B. R., Hirschman, S. Z., Axelrod, J. A. Current patterns of infection in multiple myeloma. Am. J. Med. 52 (1972) 87–92.
Galanos, C. Physical state and biological activity of lipopolysaccharides. Toxicity and immunogenicity of the lipid A component. Z. Immunitätsforsch. Immunobiol. 149 (1975) 214–229.
Galanos, C., Freudenberg, M. A., Hase, S., Jay, F., Ruschmann, E. Biological activities and immunological properties of lipid A. In:Schlessinger, D. (ed.): Microbiology. American Society for Microbiology, Washington D. C. 1977, pp. 269–276.
Galanos, C., Lüderitz, O., Rietschel, E. T., Westphal, O. Newer aspects of the chemistry and biology of bacterial polysaccharides, with special reference to their lipid A component. Int. Rev. Biochem. 14 (1977) 239–335.
Galanos, C., Lüderitz, O., Westphal, O. Preparation and properties of antisera against the lipid A component of bacterial lipopolysaccharides. Eur. J. Biochem. 24 (1971) 116–122.
Galanos, C., Freudenberg, M. A., Jay, F. A., Nerkar, D., Veleva, K., Brade, H., Strittmatter, W. Immunogenic properties of lipid A. Rev. Infect. Dis. 6 (1984) 546–552.
Fink, P. C., Galanos, C. Determination of anti-lipid A and lipid A by enzyme immunoassay. Immunobiology 158 (1981) 380–390.
Mattsby-Baltzer, I., Alving, C. R. Antibodies to lipid A: occurrence in humans. Rev. Infect. Dis. 6 (1984) 553–557.
Durie, B. G., Salmon, S. E. A clinical staging system for multiple myeloma. Cancer 36 (1975) 842–854.
Engvall, E., Perlmann, P. Enzyme-linked immunosorbent assay, ELISA. III. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tube. J. Immunol. 109 (1972) 129–135.
Peest, D., Holm, G., Mellstedt, H., Petterson, D. In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma. Scand. J. Immunol. 15 (1982) 595–603.
Marget, W., Weiß, M., Ruhland, B. Lipid A antibody determinations using ELISA on patients at a children's hospital: a preliminary report. Infection 11 (1983) 84–86.
Mattsby-Baltzer, I., Claesson, I., Hanson, L. A., Jodal, U., Kaijser, B., Lindberg, U., Peterson, H. Antibodies to lipid A during urinary tract infection. J. Infect. Dis. 144 (1981) 319–328.
Ahlstedt, S., Carlsson, B., Hanson, L. Å., Kaijser, B., Mattsby-Baltzer, I., Sohl-Akerlund, A. Applications of the ELISA for determination of immunoglobulin class specificEscherichia coli antibodies. Scand. J. Immunol. (Suppl.) 7 (1978) 119–124.
Mattsby-Baltzer, I., Kaijser, B. Lipid A and anti-lipid A. Infect. Immun. 23 (1979) 758–763.
Salonen, E. M., Vaheri, A. Rapid solid-phase enzyme immunoassay for antibodies to viruses and other microbes: effects of polyethylene glycol. J. Immunol. Methods 41 (1981) 95–103.
Bruins, S. C., Stumacher, R., Johns, M. A., McCabe, W. R. Immunization with R mutants ofSalmonella minnesota. III. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect. Immun. 17 (1977) 16–20.
McCabe, W. R., Bruins, S. C., Craven, D. E., Johns, M. Cross-reactive antigens: their potential for immunization-induced immunity to gram-negative bacteria. J. Infect. Dis. (Suppl.) 136 (1977) 161–166.
Mullan, N. A., Newsome, P. M., Cunnington, P. G., Palmer, G. H., Wilson, M. E. Protection against gram-negative infections with antiserum to lipid A fromSalmonella minnesota R595. Infect. Immun. 10 (1974) 1195–1201.
Mattsby-Baltzer, I., Hanson, L. Å., Olling, S., Kaijser, B. ExperimentalEscherichia coli ascending pyelonephritis in rats: active peroral immunization with liveEscherichia coli. Infect. Immun. 35 (1982) 647–653.
Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., Braude, A. I Treatment of gram-negative bacteremia and shock with human antiserum to a mutantEscherichia coli. N. Engl. J. Med. 307 (1982) 1225–1230.
Rioux-Darrieulat, F., Parant, M., Chedid, L. Prevention of endotoxin-induced abortion by treatment of mice with antisera. J. Infect. Dis. 137 (1978) 7–13.
Rietschel, E. T., Galanos, C. Lipid A antiserum-mediated protection against lipopolysaccharide and lipid A-induced fever and skin necrosis. Infect. Immun. 15 (1977) 34–49.
Westenfelder, M., Galanos, C., Madson, P. O. Experimental lipid A-induced nephritis in the dog. Invest. Urol. 12 (1975) 337–345.
Westenfelder, M., Galanos, C., Madson, P. O., Marget, W. Pathological activities of lipid A: Experimental studies in relation to chronic pyelonephritis. In:Schlessinger, D. (ed.): Microbiology. American Society for Microbiology, Washington D. C. 1977, pp. 277–279.
Lachman, E., Pitsoe, S. B., Gaffin, S. L. Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin. Lancet I (1984) 981–983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stoll, C., Schedel, I. & Peest, D. Serum antibodies against common antigens of bacterial lipopolysaccharides in healthy adults and in patients with multiple myeloma. Infection 13, 115–119 (1985). https://doi.org/10.1007/BF01642869
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01642869